Home   /  Find a Trial  /  See All TrialsHELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777Click to print page Print
 

See All Trials

QuickViews

Match by Tumor Type:

Newly Diagnosed (Stage I-III)
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)
Inflammatory Breast Cancer
Biomarker status:
 Hormone-positive (ER+ and/or PR+)
 HER2-positive (HER2+)
 Triple negative (ER-/PR-/HER2-)

View by Trial Type:

Treatment:

 

Non-Treatment:

see All Trials

Sort by zip code:  

 

Share

Facebook
Twitter
Twitter

 
Screening

MRI in Women Who are Healthy, High Risk or Have Breast Cancer

Breast MRI in Women With Known or Suspected Breast Cancer and in Healthy Participants (NCT00474604)

Summary

Magnetic Resonance Imaging (MRI) is a sensitive method for detecting breast cancer that has been useful in evaluating women who are at high risk for breast cancer. In addition to standard MRI, three new methods are currently being studied: Magnetic Resonance Spectroscopy (MRS) provides information about the chemical make-up of the tumor tissue, Dynamic Contrast-Enhanced MRI (DCE-MRI) uses faster imaging and a contrast material to provide information about the tumor's blood vessels, and Diffusion-weighted MRI (DW-MRI) creates images that provide information about the tumor tissue. This study will compare how well these three different MRI methods find and characterize breast tumors, compared to standard MRI. Women who have been recently diagnosed or suspected to have breast cancer, as well as healthy volunteers, are eligible for this study.

Information About Mammography Screening for Women Age 75 and Older

Randomized Trial of a Mammography Decision Aid for Women Aged 75 and Older (NCT02198690)

Summary

It is not known whether the benefits of mammography screening outweigh the risks in women age 75 and older. To improve older women's understanding of the benefits and risks of mammography screening, researchers have developed a pamphlet that provides information about mammography specifically for this age group. This study is investigating whether the pamphlet improves older women's decision-making about mammography screening. To be eligible, women must be between the ages of 75 and 89.

Whole Breast UltraSound for Screening Women With Dense Breasts

Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT (Also Known as "DBTUST-Dense Breast Tomosynthesis / Ultrasound Screening Trial") (NCT02643966)

Summary

To take part in this study, you must be between the ages of 40 and 75 and have been told that you have dense breast tissue. Mammography does not work as well in women with dense breast tissue. This study is looking at whether breast ultrasound (WBUS) is better than Digital Breast Tomosynthesis (DBT) at finding tumors that mammography misses in women with dense breast tissue. Whole breast ultrasound (WBUS) uses ultrasound to create an image of the entire breast. Digital Breast Tomosynthesis (DBT) creates a 3-dimensional picture of the breast using X-rays.

Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography

Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening (NCT02310698)

Summary

Researchers are trying to identify the best imaging technologies to use along with mammography. Breast ultrasound is sometimes used as an additional test. Studies have shown that it can detect cancers that are not seen on regular mammography. Contrast Enhanced Digital Mammography (CEDM) is an FDA-approved form of mammography. It uses a dye injected into a vein to "highlight" areas of increased blood supply, which may indicate the presence of cancer cells. CEDM has been shown to detect cancer cells that are not seen on a regular mammogram. This study is comparing the effectiveness of CEDM and breast ultrasound when used along with mammography. To be eligible, a woman must be scheduled to receive contrast enhanced digital mammography alone or with whole breast screening ultrasound or full field digital mammography on the same day or within 30 days of one another.

A Blood Test for Circulating Tumor Cells for Cancer Screening

Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma (NCT01322750)

Summary

Scientists are trying to identify effective new techniques for breast cancer screening. Researchers now believe that breast cancer cells can leave the breast and move through the blood stream to other parts of the body before the tumor is even clinically detectable. Reliable and accurate detection of these circulating tumor cells (CTCs) is now possible with a simple blood test. The goal of this research is see whether a blood test for CTCs could provide a simple, reliable, cost-effective form of breast cancer screening. The aim of this specific study is to evaluate whether individuals with CTCs and no other signs of malignancy have clinically undetectable breast cancer. To be eligible, participants must be military health care beneficiaries.

Patient Navigation for Breast/Cervical Cancer Screening for Muslim-American Women in NYC

Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City (NCT03081507)

Summary

To take part in this study, you must identify as Muslim, live in New York City and not have been diagnosed with breast or cervical cancer. It must also be more than two years since you had a mammogram. This study is investigating whether a patient navigation program designed specifically for Muslim-American women increases their participation in screening programs for breast and cervical cancer.